Table 1. Clinical trials and products of CAR-NK cell therapy.
| Sources of NK cells | Trial identifier | Product name | Tumor type | Target | Stage | Status |
| CAR-NK, chimeric antigen receptor-natural killer; PB, peripheral blood; CB, cord blood; NHL, non-Hodgkin lymphoma; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; MDS, myelodysplastic neoplasms; MM, multiple myeloma; BCL, B-cell lymphoma; CLL, chronic lymphocytic leukemia; HER2, human epidermal growth factor receptor 2. *, In this trail, CAR structure refered to novel chimeric costimulatory converting receptor, comprising mainly extracellular domain of PD1, transmembrane and cytoplasmic domains of NKG2D, and cytoplasmic domain of 41BB. | ||||||
| PB-NK | NCT05645601 | JD010 | B-cell malignancies | CD19 | Phase I | Recruiting |
| NCT05410717 | − | Ovarian cancer, testis cancer and other endometrial cancers |
Claudin6 | Phase I/IIa | ||
| NCT05487651 | KUR-502 | B-cell NHL or leukemia | CD19 | Phase I | Recruiting | |
| NCT03692637 | − | Epithelial ovarian cancer | Mesothelin | Early phase I | Unknown status | |
| NCT00995137 | − | B-lineage ALL | CD19 | Phase I | Completed | |
| NCT01974479 | − | B-lineage ALL | CD19 | Phase I | Suspended | |
| NCT03415100 | − | Metastatic solid tumors | NKG2D ligands | Phase I | Unknown status | |
| NCT05020678 | NKX019 | B-cell malignancies | CD19 | Phase I | Recruiting | |
| NCT04623944 | NKX101 | AML or MDS | NKG2D ligands | Phase I | Recruiting | |
| CB-NK | NCT05247957 | − | AML | NKG2D ligands | Phase I | Terminated |
| NCT05472558 | − | B-cell NHL | CD19 | Phase I | Recruiting | |
| NCT04796675 | − | B-cell malignancies | CD19 | Phase I | Recruiting | |
| NCT05922930 | − | Ovarian cancer, mesonephric-like adenocarcinoma, and pancreatic cancer |
TROP2 | Phase I/II | Not yet recruiting | |
| NCT05110742 | − | T-cell malignances | CD5 | Phase I/II | Not yet recruiting | |
| NCT05008536 | − | MM | BCMA | Early phase I | Recruiting | |
| NCT03056339 | − | B-cell malignancies | CD19 | Phase I/II | Completed | |
| NCT05092451 | − | Leukemia, lymphoma, or multiple myeloma | CD70 | Phase I/II | Recruiting | |
| NCT05667155 | − | B-cell NHL | CD19, CD70 | Phase I | Recruiting | |
| NCT05020015 | − | B-cell NHL or indolent NHL | CD19 | Phase II | Recruiting | |
| NCT05703854 | − | Renal cell carcinoma, mesothelioma and osteosarcoma | CD70 | Phase I/II | Recruiting | |
| NCT05842707 | − | B-cell NHL | CD19, CD70 | Phase I/II | Recruiting | |
| NCT05008575 | − | AML | CD33 | Phase I | Recruiting | |
| NK-92 | NCT02944162 | − | AML | CD33 | Phase I/II | Unknown status |
| NCT03940833 | − | MM | BCMA | Phase I/II | Unknown status | |
| NCT02892695 | PCAR-119 | Leukemia, lymphoma | CD19 | Phase I/II | Unknown status | |
| NCT02742727 | − | Leukemia, lymphoma | CD7 | Phase I/II | Unknown status | |
| NCT02839954 | − | Hepatocellular carcinoma, non-small cell lung cancer, pancreatic carcinoma, triple-negative invasive breast carcinoma, malignant glioma of brain, colorectal carcinoma, gastric carcinoma |
MUC1 | Phase I/II | Unknown status | |
| NCT03383978 | − | Glioblastoma | HER2 | Phase I | Recruiting | |
| NCT03656705 | − | Non-small cell lung cancer | −* | Phase I | Completed | |
| iPSC-NK | NCT05182073 | FT576 | MM | BCMA | Phase I | Recruiting |
| NCT04245722 | FT596 | BCL, CLL | CD19 | Phase I | Active, not recruiting | |
| NCT04555811 | FT596 | NHL | CD19 | Phase I | Active, not recruiting | |
| NCT05395052 | FT536 | Non-small cell lung cancer, colorectal cancer, breast cancer, ovarian cancer, pancreatic cancer, head and neck cancer, gastroesophageal cancer | MICA/ MICBα3 |
Phase I | Active, not recruiting | |
| NCT05336409 | CNTY-101 | B-cell malignancies | CD19 | Phase I | Recruiting | |